- Home
- WPM vs ALNY Comparison
WPM vs ALNY Comparison
Compare WPM & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPM
- ALNY
- Stock Information
- Founded
- WPM 2004
- ALNY 2002
- Country
- WPM Canada
- ALNY United States
- Employees
- WPM N/A
- ALNY N/A
- Industry
- WPM Precious Metals
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- WPM Basic Materials
- ALNY Health Care
- Exchange
- WPM Nasdaq
- ALNY Nasdaq
- Market Cap
- WPM 38.5B
- ALNY 38.1B
- IPO Year
- WPM 2004
- ALNY 2004
- Fundamental
- Price
- WPM $86.70
- ALNY $304.56
- Analyst Decision
- WPM Strong Buy
- ALNY Strong Buy
- Analyst Count
- WPM 9
- ALNY 25
- Target Price
- WPM $84.89
- ALNY $324.54
- AVG Volume (30 Days)
- WPM 1.8M
- ALNY 1.1M
- Earning Date
- WPM 05-08-2025
- ALNY 07-31-2025
- Dividend Yield
- WPM 0.76%
- ALNY N/A
- EPS Growth
- WPM 4.62
- ALNY N/A
- EPS
- WPM 1.36
- ALNY N/A
- Revenue
- WPM $1,458,244,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- WPM $38.25
- ALNY $30.28
- Revenue Next Year
- WPM $2.93
- ALNY $30.25
- P/E Ratio
- WPM $63.37
- ALNY N/A
- Revenue Growth
- WPM 32.76
- ALNY 17.21
- 52 Week Low
- WPM $51.96
- ALNY $146.79
- 52 Week High
- WPM $87.42
- ALNY $306.00
- Technical
- Relative Strength Index (RSI)
- WPM 60.38
- ALNY 68.20
- Support Level
- WPM $84.46
- ALNY $284.73
- Resistance Level
- WPM $87.12
- ALNY $295.44
- Average True Range (ATR)
- WPM 1.85
- ALNY 9.96
- MACD
- WPM 0.40
- ALNY 1.27
- Stochastic Oscillator
- WPM 96.41
- ALNY 97.29
About WPM Wheaton Precious Metals Corp (Canada)
Wheaton Precious Metals Corp is a precious metal streaming company. The company metal streaming company which generates its revenue primarily from the sale of precious metals (gold, silver and palladium) and cobalt. Its reportable segment includes: Gold, Silver, Palladium, Platinum, Cobalt, and Other.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.